Pfizer’s Breakthrough Therapy Offers Hope to Patients Despite Hefty Price Tag
The Food and Drug Administration’s approval of Pfizer’s (PFE) Beqvez marks a significant milestone in the treatment landscape for hemophilia B, a rare genetic bleeding disorder affecting over 7,000 individuals in the U.S. With Beqvez being Pfizer’s first-ever gene therapy to receive clearance in the U.S., the drug represents a leap forward in addressing unmet medical needs for patients with moderate to severe hemophilia B.
Beqvez, designed as a one-time treatment, aims to enable patients to produce factor IX themselves, thereby preventing and controlling bleeding episodes associated with hemophilia B. This novel approach offers an alternative to the often-cumbersome standard treatment regimen involving frequent factor IX infusions.
Dr. Adam Cuker, director of Penn’s Comprehensive and Hemophilia Thrombosis Program, hailed Beqvez as potentially transformative for appropriate patients, reducing both the medical burden and treatment disruptions over the long term.
Despite its promise, Beqvez comes with a hefty price tag of $3.5 million before insurance and rebates, positioning it as one of the most expensive drugs in the U.S. Pfizer’s investment in gene and cell therapies, including Beqvez, underscores the company’s commitment to advancing innovative treatments for rare diseases and solidifying its position in the evolving healthcare landscape.
You might like this article:Biodexa’s Acquisition of eRapa Marks Milestone in FAP Treatment Development
